KU-55933 (ATM Kinase Inhibitor)

Name: KU-55933 (ATM Kinase Inhibitor)
Brand: Selleck Chemicals
SKU: S1092
Rating: 5 (262 reviews)

For research use only.

Catalog No.S1092

262 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

CAS No. 587871-26-9

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/K_i of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 262 publications

Nat Genet, 2021, 10.1038/s41588-021-00893-0

PubMed: 34267371 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(20)30658-9

PubMed: 33450196 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Cancer Cell, 2017, 32(3):342-359

PubMed: 28898696 ( click the link to review the publication )

Science, 2016, 352(6283):353-8

PubMed: 27013428 ( click the link to review the publication )

Cell, 2016, 167(6):1571-1585.e18

PubMed: 27839864 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14328

PubMed: 25799992 ( click the link to review the publication )

Cell, 2013, 155(5):1088-103

PubMed: 24267891 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1048-63

PubMed: 22915751 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00315-4

PubMed: 33961796 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Sci Adv, 2021, 7(25)eabd9208

PubMed: 34144977 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3827

PubMed: 34158486 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4373

PubMed: 34272385 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkaa1290

PubMed: 33469661 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab584

PubMed: 34197606 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e201807163

PubMed: 33404608 ( click the link to review the publication )

Cancer Res, 2021, 81(18):4676-4684

PubMed: 34301763 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108713

PubMed: 33596428 ( click the link to review the publication )

Cell Rep, 2021, 34(9):108808

PubMed: 33657372 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109306

PubMed: 34192545 ( click the link to review the publication )
Autophagy, 2021, 10.1080/15548627.2021.1936932

PubMed: 34074205 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01932-0

PubMed: 34262130 ( click the link to review the publication )

Cell Mol Life Sci, 2021, 10.1007/s00018-021-03902-x

PubMed: 34308492 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):224

PubMed: 34225780 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3843

PubMed: 34359745 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:649328

PubMed: 33937245 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:650819

PubMed: 34055781 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

DNA Repair (Amst), 2021, 104:103136

PubMed: 34044336 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16751

PubMed: 34180140 ( click the link to review the publication )

Eur J Pharmacol, 2021, 907:174303

PubMed: 34217709 ( click the link to review the publication )

J Oncol, 2021, 2021:8239984

PubMed: 34484337 ( click the link to review the publication )

Cancer Invest, 2021, 1-12

PubMed: 33683975 ( click the link to review the publication )

FEBS Open Bio, 2021, 10.1002/2211-5463.13152

PubMed: 33742560 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Commun Biol, 2021, 4(1):484

PubMed: 33875784 ( click the link to review the publication )

Methods Mol Biol, 2021, 2267:103-144

PubMed: 33786788 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: None ( click the link to review the publication )

EMBO J, 2021, e106336

PubMed: 33595114 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-162979/v1

PubMed: N/A ( click the link to review the publication )

Cell Rep, 2021, 34(7):108744

PubMed: 33596421 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, 77(5):1153

PubMed: 32142686 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )
Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6178

PubMed: 33268790 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2876

PubMed: 32513994 ( click the link to review the publication )

Nucleic Acids Res, 2020, 6;48(6):2982-3000

PubMed: 31970415 ( click the link to review the publication )

Cell-Rep, 2020, 18;30-7-:2402-2415-e5

PubMed: 32075772 ( click the link to review the publication )

Cell Rep, 2020, 18;30(7):2083-2093 e5

PubMed: 32075732 ( click the link to review the publication )

Cell Rep, 2020, 14;31(2):107518

PubMed: 32294440 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Rep, 2020, 31(10):107745

PubMed: 32521270 ( click the link to review the publication )

Elife, 2020, 30;9:e51466

PubMed: 32223892 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 77(4):735-749

PubMed: 31297568 ( click the link to review the publication )

mBio, 2020, 11(1)

PubMed: 32071277 ( click the link to review the publication )

mBio, 2020, 11(3):e01190-20

PubMed: 32546626 ( click the link to review the publication )

Cancers (Basel), 2020, 28;12(6):E1388

PubMed: 32481544 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2467

PubMed: 32878283 ( click the link to review the publication )

PLoS Pathog, 2020, 16(6):e1008514

PubMed: 32479542 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2020, ATVBAHA120315206

PubMed: 33356386 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02712-7

PubMed: 32189037 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 22;12(6):4688-4710

PubMed: 32201398 ( click the link to review the publication )

DNA Repair (Amst), 2020, 87:102803

PubMed: 31991288 ( click the link to review the publication )

Sci Rep, 2020, 10(1):14455

PubMed: 32879366 ( click the link to review the publication )
Front Pharmacol, 2020, 11:601468

PubMed: 33628174 ( click the link to review the publication )

Cell Mol Biol Lett, 2020,

PubMed: 32874188 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0223463

PubMed: 31914134 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Sci Rep, 2020, 10(1):2200

PubMed: 32042076 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0600-3

PubMed: 32719556 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Nat Commun, 2020, 11(1):123

PubMed: 31913317 ( click the link to review the publication )

Med Mol Morphol, 2020, 10.1007/s00795-020-00264-4

PubMed: 32816116 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1299-1314

PubMed: 31353207 ( click the link to review the publication )

Mol Cell, 2019, 74(4):651-663.e8

PubMed: 30954402 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):87

PubMed: 30622252 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz518

PubMed: 31184714 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-3388

PubMed: 31515237 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 26(8):2194-2211.e6

PubMed: 30784599 ( click the link to review the publication )

Cell Rep, 2019, 28(3):735-745

PubMed: 31315051 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0393-7

PubMed: 31320750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766690 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 21(12):1143-1150

PubMed: 31759252 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:8535163

PubMed: 31641425 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21294-21306

PubMed: 31054162 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13097

PubMed: 31511540 ( click the link to review the publication )

J Biol Chem, 2019, 294(17):7037-7045

PubMed: 30858175 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Sci Adv, 2019, 5(5):eaav3235

PubMed: 31086816 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.215210

PubMed: 31727767 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(10):5243-5259

PubMed: 30976812 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2019, 105(4):861-874

PubMed: 31419512 ( click the link to review the publication )

J Exp Med, 2019, 216(7):1648-1663

PubMed: 31097467 ( click the link to review the publication )

J Pineal Res, 2019, 67(4):e12603

PubMed: 31370106 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):413-421

PubMed: 29531308 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 69(5):879-892.e5

PubMed: 29478807 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(3):261-269

PubMed: 29483652 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )
Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1317

PubMed: 29615613 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10119-10131

PubMed: 30165463 ( click the link to review the publication )

Sci Adv, 2018, 4(12):eaat5077

PubMed: 30585287 ( click the link to review the publication )

Cancer Res, 2018, 78(18):5363-5374

PubMed: 30054334 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403.e5

PubMed: 30257201 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Redox Biol, 2018, 14:645-655

PubMed: 29172151 ( click the link to review the publication )

Cancer Lett, 2018, 419:280-290

PubMed: 29378238 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):164

PubMed: 29415984 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):660

PubMed: 29855474 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):146

PubMed: 29396516 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(10):1645-1660

PubMed: 29849127 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(12):1874-1884

PubMed: 29921885 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):709-720

PubMed: 29328365 ( click the link to review the publication )

Virology, 2018, 523:121-128

PubMed: 30119013 ( click the link to review the publication )

Arch Biochem Biophys, 2018, 644:93-99

PubMed: 29352966 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):988-998

PubMed: 29940414 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2071-2080

PubMed: 29565449 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2363-2370

PubMed: 30066882 ( click the link to review the publication )
Radiat Res, 2018, 189(5):505-518

PubMed: 29474155 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):6608-6614

PubMed: 30405800 ( click the link to review the publication )

Radiat Environ Biophys, 2018, 57(1):31-40

PubMed: 29127482 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1697-1711

PubMed: 30323964 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(16):8311-8325

PubMed: 30010936 ( click the link to review the publication )

Blood, 2017, 129(21):2882-2895

PubMed: 28283481 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

EMBO J, 2017, 2;36(9):1261-1278

PubMed: 28320736 ( click the link to review the publication )

Genes Dev, 2017, 31(7):648-659

PubMed: 28446595 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(5):781-796

PubMed: 28325772 ( click the link to review the publication )

Cancer Lett, 2017, 390:48-57

PubMed: 28093285 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):133

PubMed: 28950914 ( click the link to review the publication )

Free Radic Biol Med, 2017, 108:750-759

PubMed: 28431961 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3019

PubMed: 28837154 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 28518141 ( click the link to review the publication )

Stem Cells Transl Med, 2017, 6(6):1504-1514

PubMed: 28544661 ( click the link to review the publication )

Sci Total Environ, 2017, 1599:375-390

PubMed: 28477133 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16115

PubMed: 29170437 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Int J Oncol, 2017, 50(1):290-296

PubMed: 27959407 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Virology, 2017, 510:9-21

PubMed: 28689087 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):338

PubMed: 28521819 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181530

PubMed: 28746371 ( click the link to review the publication )

Nutr Cancer, 2017, 69(8):1281-1289

PubMed: 29111814 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(18):10564-10582

PubMed: 28985345 ( click the link to review the publication )

Genome Biol, 2017, 18(1):224

PubMed: 29178945 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Mol Cell, 2016, 61(3):405-418

PubMed: 26774285 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(10):4745-62

PubMed: 26939887 ( click the link to review the publication )

Genes Dev, 2016, 30(3):321-36

PubMed: 26833731 ( click the link to review the publication )

J Cell Biol, 2016, 212(4):399-408

PubMed: 26880199 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.15129

PubMed: 27269284 ( click the link to review the publication )

Oncogene, 2016, 35(5):567-76

PubMed: 25893301 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16011

PubMed: 27551505 ( click the link to review the publication )

Cell Death Discovery, 2016, 10.1038/cddiscovery.2016.11

PubMed: ( click the link to review the publication )

FASEB J, 2016, 30(8):2899-914

PubMed: 27142525 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4313204

PubMed: 28042385 ( click the link to review the publication )

Cell Discov, 2016, 2:16016

PubMed: 27462463 ( click the link to review the publication )

J Immunol, 2016, 197(7):2918-29

PubMed: 27559048 ( click the link to review the publication )

J Cell Sci, 2016, 129(16):3167-77

PubMed: 27383768 ( click the link to review the publication )

Sci Rep, 2016, 6:22972

PubMed: 27026501 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 292:65-74

PubMed: 26708502 ( click the link to review the publication )
Chem Res Toxicol, 2016, 29(1):26-39

PubMed: 26630137 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(1):169-80

PubMed: 26590990 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Sci Rep, 2016, 6:27379

PubMed: 27271479 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29359-70

PubMed: 27121065 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49800-49818

PubMed: 27391441 ( click the link to review the publication )

Mutat Res Genet Toxicol Environ Mutagen, 2016, 795:1-6

PubMed: 26774662 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1004-13

PubMed: 26214134 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1446-57

PubMed: 26502055 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genes Dev, 2015, 29(11):1151-63

PubMed: 26019174 ( click the link to review the publication )

Nanoscale, 2015, 7(47):20211-9

PubMed: 26575637 ( click the link to review the publication )

Oncogene, 2015, 34(23):2978-90

PubMed: 25132270 ( click the link to review the publication )

Arch Toxicol, 2015, 89(11):2015-25

PubMed: 25294323 ( click the link to review the publication )

PLoS Genet, 2015, 11(10):e1005563

PubMed: 26430909 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(12):2217-26

PubMed: 25904336 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )
Cell Signal, 2015, 27(5):951-60

PubMed: 25683911 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142561

PubMed: 26556501 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Int J Radiat Biol, 2015, 10.3109/09553002.2015.1029595

PubMed: 25912236 ( click the link to review the publication )

Cell Biol Int, 2015, 10.1002/cbin.10439

PubMed: 25598069 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nat Neurosci, 2014, 17(6):813-21

PubMed: 24793032 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.159

PubMed: 25301067 ( click the link to review the publication )

Mol Cancer, 2014, 13:36

PubMed: 24568192 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1198-213

PubMed: 25100205 ( click the link to review the publication )

DNA Repair , 2014, 21:140-7

PubMed: 24795278 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1071-9

PubMed: 24726882 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1088-96

PubMed: 24726884 ( click the link to review the publication )

J Biol Chem, 2014, 289(23):16072-84

PubMed: 24782314 ( click the link to review the publication )

Toxicol Appl Pharm, 2014, 282(2):227-236

PubMed: 25450480 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1777-87

PubMed: 24732096 ( click the link to review the publication )

Neurotox Res, 2014, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

Radiat Res, 2014, 181(6):650-8

PubMed: 24785587 ( click the link to review the publication )
Theriogenology, 2014, 12(5):e1001856

PubMed: 24800743 ( click the link to review the publication )

Proteomes, 2014, 2, 451-467

PubMed: ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Proteomes, 2014, 2(3):451-467

PubMed: 28250390 ( click the link to review the publication )

PLoS One, 2014, 9(6):e98891

PubMed: 24902048 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Sci Signal, 2013, 6(259):ra5

PubMed: 23354688 ( click the link to review the publication )

Neurotox Res, 2013, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

FEBS Lett, 2013, 587(21):3437-43

PubMed: 24021642 ( click the link to review the publication )

PLoS One, 2013, 9(1):e84899

PubMed: 24454762 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80313

PubMed: 24282534 ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2664-2669

PubMed: 24045107 ( click the link to review the publication )

Cell Cycle, 2013, 12(7):1105-18

PubMed: 23462183 ( click the link to review the publication )

Autophagy, 2012, 8(2):236-51

PubMed: 22240589 ( click the link to review the publication )

J Immunol, 2012, 188(5):2266-75

PubMed: 22287717 ( click the link to review the publication )

J Biol Chem, 2012, 287(26):22112-22

PubMed: 22566699 ( click the link to review the publication )

J Biol Chem, 2012, 287(12):8803-15

PubMed: 22270370 ( click the link to review the publication )

Food Chem Toxicol, 2012, 55:214-21

PubMed: 23274058 ( click the link to review the publication )

Int J Radiat Biol, 2012, 88(7):507-14

PubMed: 22449004 ( click the link to review the publication )

J Virol, 2011, 85(23):12547-56

PubMed: 21917957 ( click the link to review the publication )

J Biol Chem, 2011, 286(10):8394-404

PubMed: 21148313 ( click the link to review the publication )

Mech Ageing Dev, 2011, 132(11-12):543-51

PubMed: 21945951 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description

Targets

ATM ^[1]
(Cell-free assay)

12.9 nM

In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. ^[1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
DU-145	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTNwMkezOVIh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HuO-3N1	M4K3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHwO4pYUUN3ME20MlE4OTR{IN88US=>	NH6yc3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
LAMA-84	NF;qZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX4UGdKSzVyPUSuOVg1PjVizszN	NULvbG8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
CAL-72	NUi3fGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTVwNEiwPFQh\|ryP	Mn\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
LoVo	NHXGW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXywZ2FVUUN3ME22Mlk{OjN7IN88US=>	M3vsWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HH	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmi4TWM2OD16LkK3OlcyKM7:TR?=	MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrRTWM2OD16LkK4OVc2KM7:TR?=	NUPoPIR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
KM12	NILaUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\tTWM2OD17LkKxNVQzKM7:TR?=	MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H1437	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTlwOEC5O{DPxE1?	NV3xNIhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NCI-H1838	NH;Gc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFzLkG4OlUh\|ryP	MlKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NFvLTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFzLkK0NVch\|ryP	MljsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
GOTO	NFnNNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPpOm1KSzVyPUGxMlY6QTZizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe4SWJrUUN3ME2xNU44OTh4IN88US=>	M4XjWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
ES7	NFrZ[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFzLke4PEDPxE1?	M3PTU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KP-N-YS	NI[xfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVS5OlhJUUN3ME2xNk43OzV2IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
CAL-12T	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\TSGlEPTB;MUOuOlE4KM7:TR?=	NWnrS\|R3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
COLO-684	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX2zcpFoUUN3ME2xOE4yPTZ7IN88US=>	NWjmZmZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
DOK	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPaTpQzUUN3ME2xOU4{OzJ7IN88US=>	M3fQPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
Hs-578-T	NVjGNnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M361XGlEPTB;MUWuOFE5OiEQvF2=	M{PuOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
D-423MG	NEXKO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHSxWJVKSzVyPUG1MlUzOzZizszN	NICzSGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
DBTRG-05MG	NXL5[2VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLqTWM2OD1zNT62NVEyKM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
VM-CUB-1	M{XTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWi4XGQ6UUN3ME2xOU46QDR7IN88US=>	NEK2XGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
KG-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTMXIVMUUN3ME2xOk4xQTl4IN88US=>	NELVTVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
8305C	NYjrVFg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\2cFlKSzVyPUG2MlE5QDlizszN	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HuH-7	M1PhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[4bmlEPTB;MU[uNlY4PCEQvF2=	MnvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
LXF-289	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\mTWM2OD1zNj6yO\|Q4KM7:TR?=	NF;Ke2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
NCI-H1793	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjv[FBKSzVyPUG2MlQ4OTJizszN	NUXlZ3gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	NYfj[mhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLyTWM2OD1zNj62OVY5KM7:TR?=	MkS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
GCIY	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{S3SWlEPTB;MU[uO\|kxPSEQvF2=	NX6xZWRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-MEL-28	NYTNUlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF5LkC0O\|Uh\|ryP	NYXne4tYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	NIPWPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnxd3VZUUN3ME2xO{4yOjZ7IN88US=>	NFLvc209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CTB-1	NXm1Z3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPxenJKSzVyPUG3MlIzPTlizszN	M2[3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H82	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF5LkS1O\|Mh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HCC2998	NXzUWZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTF5Lk[3N\|Mh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
NCI-H2030	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF6LkG5PVch\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HuP-T3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHyTWM2OD1zOD61PFg5KM7:TR?=	M2mxZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
697	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrOTWM2OD1zOT6wNlAyKM7:TR?=	NHjz[lA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MLMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LtXWlEPTB;MUmuNFU2PyEQvF2=	NVOzUWdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HCC70	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnH4TWM2OD1zOT60PFkh\|ryP	NUflc2xlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
A704	M2XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF7LkizNFUh\|ryP	M1PXO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
D-283MED	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\KTWM2OD1{MD61N\|M6KM7:TR?=	NF7oOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
U031	NV3sS3czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJzLkG0PFkh\|ryP	M3SyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HSC-3	NHKwOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfsWoJKSzVyPUKxMlE5OzVizszN	NWDTd\|VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
JVM-3	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorYTWM2OD1{Mj61NFYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
Mewo	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4CyUGlEPTB;MkKuOVA4OyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
YH-13	NUPRTZo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn:xTWM2OD1{Mj61NVI{KM7:TR?=	MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	NWfSeoFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXL3OYlTUUN3ME2yNk42QDd7IN88US=>	NICwZ\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC2157	NXLtepNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLpcGk1UUN3ME2yNk45ODV2IN88US=>	MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SNU-449	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjMN\|JKSzVyPUKyMlg4PDhizszN	NVzpbGVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{H1[2lEPTB;MkKuPVYh\|ryP	NF\TSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CHL-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3ITWM2OD1{Mz63NlkzKM7:TR?=	NYPoeXlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-MEL-30	NVy1c4N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDMTWM2OD1{ND60OlYzKM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
PANC-08-13	NVzWcmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\OVWpKSzVyPUK1MlA6OzhizszN	MnvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NX;mOFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\EcXQ3UUN3ME2yOU4yQDV6IN88US=>	M{fPZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
BFTC-905	NEi4SFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TsV2lEPTB;MkWuOVk1PCEQvF2=	M{HZZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
GI-1	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTJ3LkewOVUh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MDA-MB-415	M{LoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXf3RWF3UUN3ME2yOk42ODN\|IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
GT3TKB	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJ4LkWzOFIh\|ryP	NWTlV4U{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
DEL	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHOTWM2OD1{Nj64N\|U3KM7:TR?=	NInvN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
KOSC-2	NX32bY81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrHTWM2OD1{Nj65NFc2KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
RVH-421	M1HGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjaSWtKSzVyPUK3MlI6OjFizszN	MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
EW-13	M2XEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJ5LkSzNFgh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
639-V	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTJ5LkWxNVkh\|ryP	M2fDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
A2780	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF36S\|BKSzVyPUK3MlY1OSEQvF2=	NXG4e3B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SW982	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJ5LkmwOVIh\|ryP	NHf1bVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
SW1710	NGD5c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjsTWM2OD1{OD6wPVgyKM7:TR?=	NWT6Snl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HCC1569	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJ6LkS4PVch\|ryP	NWHrd2tWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
MV-4-11	NGrMWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7qXpFsUUN3ME2yPE42PzN3IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
BHT-101	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV65cXVVUUN3ME2yPE43PTd{IN88US=>	MnT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
Ca9-22	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\sTWM2OD1{OD63NVQh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HAL-01	NFm4VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPp[YRPUUN3ME2yPE44PjF3IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
D-263MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moq1TWM2OD1{OT6zOFQh\|ryP	M4HueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NEC8	NGTpUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnxe5k1UUN3ME2yPU42PTR6IN88US=>	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
EKVX	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjOUHBQUUN3ME2zNU42QDR5IN88US=>	NVfiPFZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
EM-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT6TWM2OD1\|MT62N\|A1KM7:TR?=	NFvyZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
MFM-223	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;6[2lEPTB;M{GuPFA6QCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrTO414UUN3ME2zNk4yPDB4IN88US=>	M3ewelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HuO9	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzTTWM2OD1\|Mj61NlgzKM7:TR?=	M3PFb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
MHH-PREB-1	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS0R\|FnUUN3ME2zNk43OjN2IN88US=>	NYC5emRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
OVCAR-4	NVHtV3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPiN3NvUUN3ME2zNk45OzZ\|IN88US=>	M2fR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H1648	M3zRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfoZ2lKSzVyPUOyMlg3PTFizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MKN1	M1fVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\KTWM2OD1\|ND6xNVAyKM7:TR?=	MljXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
KYSE-450	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\UZYtoUUN3ME2zOE43PDR2IN88US=>	M4TG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
ES8	NXHDe4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\s[GtKSzVyPUO0Mlg6PzVizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MS-1	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTN2Lkm1OVQh\|ryP	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HOP-92	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTJTWM2OD1\|NT65Nlc4KM7:TR?=	M3zmPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SKG-IIIa	NVXzPFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLmbpBKSzVyPUO2MlI2PjFizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
TE-11	NInKPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHeyW5VKSzVyPUO2MlUzPDNizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
SK-NEP-1	M4\VUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[5UWVoUUN3ME2zO{43PzR2IN88US=>	M1TPS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
DB	NHXlPXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvpcZlKSzVyPUO3MlkyQDVizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
IA-LM	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTxOI5mUUN3ME2zPE4xOjN7IN88US=>	NIPCSG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
COLO-829	NYHK[lhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1f5OmlEPTB;M{iuOFE2QSEQvF2=	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknhTWM2OD1\|OT6xOFA5KM7:TR?=	NIjtcYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CAL-51	NV:3ZZduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3nPZE5UUN3ME20NE4xPjF{IN88US=>	NInae409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
NCI-H2228	NYfFc4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmj5TWM2OD12MD6zOlYzKM7:TR?=	NWTEXIdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
C32	NIPLO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3kcYZKSzVyPUSwMlQxOjRizszN	MknaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
KU-19-19	NEXnWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzXTWM2OD12MD63Olg{KM7:TR?=	M1Kx[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KNS-62	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rrWmlEPTB;NECuPFM5OSEQvF2=	NUi1foRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
FADU	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnz[XNKSzVyPUSxMlI2ODJizszN	NHfhS3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CAL-33	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzhZWJnUUN3ME20Nk43PzR7IN88US=>	M4DofVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CHP-134	NVnzPWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj3cIN3UUN3ME20Nk45PDl4IN88US=>	NHTUNYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HDLM-2	M3vFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLwSFVTUUN3ME20Nk46ODh2IN88US=>	M{fi[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NBsusSR	NYDPbWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Tsb2lEPTB;NEOuNFczPSEQvF2=	M2HvNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SW954	M2jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX2S5JmUUN3ME20N{4yODV\|IN88US=>	NHu1b3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC1806	NUD1Rml2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYK3ZoJCUUN3ME20N{41OTFizszN	MoXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe0TWM2OD12Mz60OVg3KM7:TR?=	NIDxb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
A549	NYPkd\|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjhdZVwUUN3ME20N{46OzFizszN	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NKM-1	NXLsSFJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPmOXRKSzVyPUSzMlk2PThizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
DMS-273	M{j2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3Z[IVKSzVyPUS0Mlc2PjdizszN	NH7yZY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
TYK-nu	NHXDVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkT1TWM2OD12NT6xNlM1KM7:TR?=	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
KALS-1	NUPrWoJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTR3LkG0OkDPxE1?	NUmzeZJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
A101D	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjpTWM2OD12NT60OFU3KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
G-361	M3ixPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvkTpRKSzVyPUS2MlIyOzhizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KARPAS-299	NIPK[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULudnYxUUN3ME20Ok4{PTF4IN88US=>	NXHxOFJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
RS4-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\B[5k4UUN3ME20Ok42PDJizszN	NXrTVm1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HT-1376	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFW2UolKSzVyPUS2Mlc1OjZizszN	NVTVZWlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-N-AS	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrwTWM2OD12Nj63PFIzKM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MG-63	NF7ONYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHIfolJUUN3ME20Ok46ODN4IN88US=>	NEC5[4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
EPLC-272H	MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLlTWM2OD12Nj65OVA{KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
BALL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TuemlEPTB;NEeuPFMzKM7:TR?=	M4OxcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
LCLC-97TM1	NYHQVWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf4NpBqUUN3ME20PE4zODJizszN	Mn21QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HO-1-N-1	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XEc2lEPTB;NEiuPVY4PiEQvF2=	M4f3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
MFE-280	NULzTVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDNd5cxUUN3ME20PU41PjF5IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
NCI-H526	NH7zeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTR7LkixOlMh\|ryP	NHPIdVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
D-566MG	M3vIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLNNHNNUUN3ME20PU46ODl4IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
BB30-HNC	NHXG[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFm5OYdKSzVyPUS5Mlk1QThizszN	M1rUb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SK-N-DZ	M{Hldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fxbGlEPTB;NUCuNFQ5OSEQvF2=	NGm0S5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HepG2	M3m3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPkNVDDqM7:TR?=	NVv6bpBbOjRiaB?=		MnfFZoxw[2u\|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=>	M1ntbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK3NVI{Lz5{NUWyO\|EzOzxxYU6=
HepG2	MX\GeY5kfGmxbjDBd5NigQ>?	NVP5WW5HOTEEoN88US=>	NVfG[YxvOjRiaB?=		NXX1VlRZe3WycILld5NmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wczDv[kBCXE1ib36gV4VzOTl6MTygR4hsOSCxbjDT[ZI{PDVuIFPob\|Ihd25iVHjyOlgtKGGwZDDD[IszKG:wIGT5dlE2KGmwZIXj[YQh[nliU1OtTWlKOw>?	NV7sV\|ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlcyOjNpPkK1OVI4OTJ\|PD;hQi=>
KATO III	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkD0Nk42NzVxNz61JO69VQ>?		NF;wd2FFVVOR	NGHGPZdmdmijbnPld{B1cGVidH;4bYNqfHlib3[gc4xieGG{aXK=	NVvUS4ZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OFE4OThpPkK0PFQyPzF6PD;hQi=>
hTCEpi	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlK2NVAh\|ryP		M1\qSmROW09?	NF\BRmlxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF?	Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{C4N\|UoRjJ2M{ewPFM2RC:jPh?=
MCF10A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYGySnBROTBizszN	M1HY[lI1KGh?	MX;EUXNQ	M{TlVJBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiR1G=	M4\1blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUWwOVk2Lz5{NEG1NFU6PTxxYU6=
HL-60	NHvGU2hHfW6ldHnvckBCe3OjeR?=	M1nh[VExKM7:TR?=	NXKxNmR3OC53IHi=	MULEUXNQ	MnX5doVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLi	NXznTZZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|Q1OTFpPkKzPVM1PDFzPD;hQi=>
MCF-7	NEOyb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHwd\|IyNTFyMN88US=>	NWX1WY1uOjRiaB?=	NUW1b4xGTkKV	M3[0[olvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25?	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOEWzOFcoRjJ\|MUi1N\|Q4RC:jPh?=
HeLa	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHuWVFHOS1zMEFOwG0>	M17wNlI1KGh?	M3XSNGZDWw>?	MkfMbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>?	NEjFNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G4OVM1Pyd-MkOxPFU{PDd:L3G+
SH-SY5Y	MYjGeY5kfGmxbjDBd5NigQ>?	MnG3NVDDqM7:TdMg	MmHmNlQhcA>?		M4Xxc4lvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YheDV\|	M320clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkK3Nlk1Lz5{Mk[yO\|I6PDxxYU6=
IMR-32	NEHENY1HfW6ldHnvckBCe3OjeR?=	Moj0NVDDqM7:TdMg	NFPjdHIzPCCq		MWfpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>?	M2\UOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NkK3Nlk1Lz5{Mk[yO\|I6PDxxYU6=
A549	M1jxXWZ2dmO2aX;uJGF{e2G7	NW\sUI81OTEEoN88UeKh	MoGzNUBp		M3XaOpN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36=	NXLCd3dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVk{OjFpPkKyOVU6OzJzPD;hQi=>
T47D	NYjpcVIyTnWwY4Tpc44hSXO\|YYm=	MVWyNOKhdU1?	MX[yOEBp	NIO5dWpFVVOR	NFKyRWlxemW4ZX70d{BKWi2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJGnPwkMQsR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF2NEiwOUc,OjFzNES4NFU9N2F-
A29 MEF	NV3oflhITnWwY4Tpc44hSXO\|YYm=	NXTPO3R6OTEEoN88UeKh	NHvKSFAycA>?		NYTNb3l{[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O\|PDqA>?	MmXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNUO3PFEoRjJyMEWzO\|gyRC:jPh?=
MDA-MB-453	M1K4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLQd4Y2NTRyIN88US=>	NIDQPFE4OiCq		MV3JR\|UxKG:oIEGwJO69VQ>?	Mn36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNUO3PFEoRjJyMEWzO\|gyRC:jPh?=
PC-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXVb2w2NTRyIN88US=>	M3y2TlczKGh?		NEfTdGxKSzVyIH;mJFExKM7:TR?=	M2e1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEWzO\|gyLz5{MEC1N\|c5OTxxYU6=
U2OS	NHzKNWlHfW6ldHnvckBie3OjeR?=				MVHJcohq[mm2aX;uJI9nKEGWTTDpckBpfW2jbjDVNm9UKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gdFU{KHCqb4PwbI9zgWyjdHnvckBifCCVZYKxOUBz\XOrZIXlMEBKSzVyIE2gNE4zPSEQvF2u	NWi3ZZJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|I6PjVpPkK2OlMzQTZ3PD;hQi=>
MCF7	M4fnRmZ2dmO2aX;uJIF{e2G7		NXqxOJc5OSCqch?=		NXjsTnk{UW6qaXLpeIlwdiCxZjDBWG0hc2mwYYPlJIlvKGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgNUBpeiCkeTDpcY12dm:obIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkOg{txONg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ\|Mkm2OUc,OjZ4M{K5OlU9N2F-
BJ	NV\tXZhjTnWwY4Tpc44h[XO\|YYm=	NIjIfWoyOCC3TR?=	MmO1NVAh\GG7cx?=		NIf1WodUfXCycnXzd4lwdiCxZjDz[Y5me2OnbnPlJIlvKGi3bXHuJGJLKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhdnWvYnXyJIF1KDFyIIXNJIFnfGW{IEGwJIRigXNiYomgd4Vv\XOlZX7j[UBz\X[ncoPhcEBie3OjeR?=	NH;nblI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke2O\|A5PSd-MU[3OlcxQDV:L3G+
BJ	M3PyWmZ2dmO2aX;uJIF{e2G7	NYf3W2pQOTBidV2=	M1i4TFExKGSjeYO=		NEfFdVBKdmirYnn0bY9vKG:oIHH0ZZhq[SC2ZXzhcodq\WO2YYPpZU1ufXSjdHXkJIlvKGi3bXHuJGJLKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhdnWvYnXyJIF1KDFyIIXNJIFnfGW{IEGwJIRigXNiYomgd4Vv\XOlZX7j[UBz\X[ncoPhcEBie3OjeR?=	NEjlSpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke2O\|A5PSd-MU[3OlcxQDV:L3G+
MCF7	NFLo[GNHfW6ldHnvckBie3OjeR?=	NXTyToROOTBidV2=	MkTXNVAhdWmwcx?=		NWf3U3Q3W2Wwc3n0bZpifGmxbjDv[kBqdm[{YYLl[E1qdmS3Y3XkJGRPSSCmYX3h[4UhcW5iaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2:ub375JIZwem2jdHnvckBifCBzMDD1UUBxemW2cnXheIVlKG[xcjCxNEBucW6\|IH\vcIxwf2WmIHL5JIlzemGmaXH0bY9vKG[xcjC0JIhzeyCvZXHzeZJm\CCjZoTldkAyOCCmYYnzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nJIFv[Wy7c3nz	M{OxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOyPVY2Lz5{Nk[zNlk3PTxxYU6=
SK-N-MC	M{nvNpFJXFNiYYPzZZk>				NHzwTnVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MmnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT(Ser473) / p-AKT(Thr308); PubMed: 22739265 Chin J Cancer Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖 PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; PubMed: 22739265 Chin J Cancer ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤 ATM-S1981 / ATM / p-p53(S15) / p53 ; PubMed: 20639198 J Biol Chem Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖 p21 / p27 / p53 ; PubMed: 20177072 J Biol Chem HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.	22739265 20639198 20177072
Immunofluorescence	p-S824 KAP1 / ZEBRA ; PubMed: 28249048 PLoS Pathog HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.	28249048

In vivo

Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Purified enzyme assays: ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl₂, 250 mM KCl, 500 μM EDTA, 100 μM Na₃VO₄, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH₂-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl₂, 2 mM MnCl₂, 50 μM Na₃VO₄, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research: ^[1]	- Collapse Cell lines: U2OS cells Concentrations: 10 μM Incubation Time: 2 hours Method: U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m²) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells Dosages: 10 μM Administration: -- (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	33 mg/mL (83.44 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download KU-55933 (ATM Kinase Inhibitor) SDF

Molecular Weight	395.49
Formula	C₂₁H₁₇NO₃S₂
CAS No.	587871-26-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

ATM/ATR Inhibitor in Clinical Trial

BEZ235 (NVP-BEZ235, Dactolisib) : Phase II for Advanced Endometrial Carcinoma.

Related ATM/ATR Products

Ceralasertib (AZD6738) ^New

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
Chloroquine diphosphate

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).
ETP-46464

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Choose Your Country or Region

By Signaling Pathways

By product type

KU-55933 (ATM Kinase Inhibitor)